Uploaded December 2024 | Updated September 2026, 2 weeks ago
This talk explores how Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the pharmaceutical industry, particularly in the detection of protein crystals, a crucial step in many drug discovery pipelines. It focuses on how specialized AI models can improve the speed of crystallization screening, helping scientists identify protein structures more efficiently.
Using real-world case studies, the talk demonstrates how AI can outperform traditional methods. It describes a collaboration with AstraZeneca. It shows how even small datasets can significantly boost AI model performance, enabling detection capabilities beyond human limitations.
The talk also emphasizes the importance of reproducible, user-friendly AI tools for researchers, and provides a sneak peek at an exciting project with the University of Bonn, recently accepted for publication in Nature Biotechnology.
Learn how AI is shaping the future of pharma and accelerating drug discovery. Want to learn more about what we do? Read more here: go.appsilon.com/discover-ai
_______________________________________
0:00 – Introduction: AI in drug discovery and protein crystallization
0:21 – Specialized AI: Machine learning for specific tasks
0:46 – Key Principles: Tools, reproducibility, and AI beyond human limits
1:18 – Case Study 1: Improving protein crystallization detection
3:07 – Crystallization Screening: The challenge of detecting crystals
5:02 – Marco Model: Benchmarking and improvements
8:03 – Small Data: Boosting performance with fewer images
8:54 – Case Study 2: AstraZeneca collaboration for better accuracy
10:08 – Beyond Human Limits: New AI developments
11:21 – Bonus Project: University of Bonn collaboration, Nature Biotechnology
12:06 – AI Tools: Making AI accessible to researchers
13:24 – Closing: AI's impact on pharma and drug discovery
This talk explores how Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the pharmaceutical industry, particularly in the detection of protein crystals, a crucial step in many drug discovery pipelines. It focuses on how specialized AI models can improve the speed of crystallization screening, helping scientists identify protein structures more efficiently.
Using real-world case studies, the talk demonstrates how AI can outperform traditional methods. It describes a collaboration with AstraZeneca. It shows how even small datasets can significantly boost AI model performance, enabling detection capabilities beyond human limitations.
The talk also emphasizes the importance of reproducible, user-friendly AI tools for researchers, and provides a sneak peek at an exciting project with the University of Bonn, recently accepted for publication in Nature Biotechnology.
Learn how AI is shaping the future of pharma and accelerating drug discovery. Want to learn more about what we do? Read more here: go.appsilon.com/discover-ai
_______________________________________
0:00 – Introduction: AI in drug discovery and protein crystallization
0:21 – Specialized AI: Machine learning for specific tasks
0:46 – Key Principles: Tools, reproducibility, and AI beyond human limits
1:18 – Case Study 1: Improving protein crystallization detection
3:07 – Crystallization Screening: The challenge of detecting crystals
5:02 – Marco Model: Benchmarking and improvements
8:03 – Small Data: Boosting performance with fewer images
8:54 – Case Study 2: AstraZeneca collaboration for better accuracy
10:08 – Beyond Human Limits: New AI developments
11:21 – Bonus Project: University of Bonn collaboration, Nature Biotechnology
12:06 – AI Tools: Making AI accessible to researchers
13:24 – Closing: AI's impact on pharma and drug discovery
